A critical analysis of the vesicular drug delivery system: recent advancements and prospects for the future
Vesicular system drug design has revitalised the efficacy of previous medications by effectively regulating and sustaining their therapeutic action. The objective of this study is to evaluate the feasibility of utilizing pharmaceutical interventions to target novel vesicular drug delivery systems. The objective of innovative medication administration is to minimize adverse effects while ensuring drug efficacy at a predetermined or reasonably consistent level within the body. A novel drug delivery approach is characterized by the controlled release of medication at a predetermined rate, which is determined based on factors such as therapeutic requirements, pharmacological properties, drug characteristics, physiological condition of the organism, and other relevant considerations. At present, there is a lack of medication delivery technologies that effectively achieve the aforementioned objectives while minimizing adverse effects. The utilization of vesicular systems in drug delivery has brought about changes in the understanding and application of diagnosis and therapy across different domains within the biomedical field. The vesicular drug delivery system (VDDS) serves as a means to address the disparity between the theoretical ideal and the presently accessible innovative drug delivery systems, accomplishing this by enclosing active moieties within vesicular structures. Various vesicular drug delivery systems, such as liposomes, niosomes, transferases, pharmacosomes, colloidosomes, herbosomes, sphinosomes, among others, have been developed. This review primarily focuses on the examination of various pharmacological targets, both lipiodal and nonlipoidal, within vesicular systems. Liposomes and niosomes represent innovative drug delivery systems.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.